New drug combination shrunk tumours significantly in 46% of patients with treatment-resistant form of disease

Thousands of women with ovarian cancer could benefit from a revolutionary drug combination after it was shown to shrink tumours in half of patients with an advanced form of the disease.

The pair of drugs – which work together to block the signals cancer cells need to grow – could offer a new treatment option for women with a type of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

Continue reading…
Source: The Guardian